SAO · DASA3.SA
Diagnósticos da América S.A.
R$3.01+R$0.06 (+2.03%)
Diagnósticos da América S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.01% below the high.
Loading market information…
SAO · BIOM3.SA · BRL
Stock price, earnings
Quote as of Oct 30, 2026, 07:05 PM UTC. Cached market data; not a live quote.
One-year closing-price history · BRL. Historical prices are not a forecast.
Biomm S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biomm S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biomm S.A. is a biotechnology enterprise based in Brazil. Its diverse product portfolio features pharmaceutical and healthcare solutions, including AFREZZA, a human insulin administered as an inhalation powder, and GLARGILIN, a type of glargine insulin. The company also supplies HERZUMA, a trastuzumab, and CONFORT CARE, a moisturizing foot cream. Biomm S.A. was established in 2001 and maintains its headquarters in São Paulo, Brazil.
Latest available per-share figures in BRL. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:24 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
R$3.01+R$0.06 (+2.03%)
Diagnósticos da América S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.01% below the high.
R$9.15-R$0.20 (-2.14%)
Blau Farmacêutica S.A.’s quoted price sits in the lower half of its reported 52-week range, 36.9% below the high.
R$2.50-R$0.06 (-2.34%)
Empreendimentos Pague Menos S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.19% below the high.
R$10.09-R$0.20 (-1.94%)
Dimed S.A. Distribuidora de Medicamentos’s quoted price sits in the lower half of its reported 52-week range, 38.99% below the high.
R$0.76+R$0.05 (+7.04%)
Oncoclínicas do Brasil Serviços Médicos S.A.’s quoted price sits in the lower half of its reported 52-week range, 75.24% below the high.
R$6.60-R$0.00 (0.0%)
Profarma Distribuidora de Produtos Farmacêuticos S.A.’s quoted price sits in the lower half of its reported 52-week range, 31.96% below the high.
R$2.49+R$0.03 (+1.22%)
Allianca Saude e Participacoes S.A.’s quoted price sits in the lower half of its reported 52-week range, 59.77% below the high.
R$1.34+R$0.04 (+3.08%)
Qualicorp Consultoria e Corretora de Seguros S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.28% below the high.
